
Please try another search
(Reuters) -Israeli drugmaker Teva Pharmaceutical Industries (NYSE:TEVA) Ltd said there was sufficient participation from U.S. states and local authorities to move forward with its nationwide settlement agreement to resolve opioid-related claims and litigation.
Teva said on Monday it has either already settled with or confirmed participation from 48 of the 50 states and will continue to pursue participation by the states that are yet to join. The sign-on process for states' subdivisions will now begin, it said.
The company in November finalized the settlement agreement to resolve thousands of U.S. lawsuits over the marketing of opioid painkillers and agreed to pay up to $4.25 billion, including a supply of the overdose drug naloxone.
It, however, did not admit wrongdoing.
The litigation over opioids, which began in 2017, has yielded more than $40 billion in settlements from drugmakers, distributors and pharmacy chains.
State and local authorities have said they will use the money to combat the opioid crisis.
More than 932,000 people have died since 1999 from a drug overdose, according to Federal data.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.